Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan + Iparomlimab + Tuvonralimab vs TAC as neoadjuvant therapy for HR-positive/HER2-low breast cancer
ChiCTR2600130563Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of trastuzumab rezetecan, iparomlimab and tuvonralimab in breast cancer (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Pathological complete response rate (pCR). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecaniparomlimabtuvonralimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600130563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130563.